Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, MD & CEO
Michael Thurn
MD & CEO
SPONSORED BY The Market Online